Study on Biocompatibility of Cross-linked Hyaluronic Acid Derivatives

Objective:The cross-linked production, which was prepared by HA and cross-linking agent STMP, EDC, GP through cross-linking reaction,might be used in drug delivery system(DDS). To ensure the security of clinical application,the excellent properties such as none cell toxicity, nonirritant, none general toxicity, none immunological rejection are necessary. Methods:In accordance with the request of GB/T 16886.1 on security evaluation of medical biomaterials,cell toxicity test, hemolysis test, intracutaneous stimulation test, acute toxicity test, and hypersensitive test were required. Results: Cell toxicity of HA-STMP,HA-EDC,HA-GP were all less than 1. All hypersensitive tests were eligible. But HA-EDC, HA-GP produced different degrees of slight thrill,slight toxicity, hemolysis rate,which were larger than the standard value. Conclusion:HA-STMP possesses favourable biocompatibility,which is a kind of ideal biomaterials and drug carriers.